At the European Hematology Association’s annual meeting in Vienna last week, companies reported impressive progress for the treatment of sickle cell disease.
At the 2022 Annual Congress of the European Hematology Association, researchers from the Spanish National Cancer Institute reported how high levels of the RNA-binding protein hnRNP-K could lead to bone marrow failure.
A Massachusetts Institute of Technology-led team has identified distinct midbrain circuits that contributed to both motor and psychiatric symptoms of Parkinson's disease in animal models. Activating the circuits could reverse both types of symptoms.
A central assumption about so-called synonymous mutations, which are changes in the coding sequence of proteins that do not lead to changes in its amino acid sequence, is being questioned by a study published in the June 8, 2022, issue of Nature.
Researchers have long known that the developmental regulator WNT5A plays a role in the dissemination of tumor cells. Now, investigators from Johns Hopkins University have discovered that its suppression plays a role in the growth of metastases after a period of dormancy as well.
Four scientists have shared the 2022 Kavli Prize in neuroscience, "for pioneering the discovery of genes underlying a range of serious brain disorders," together and separately.
By analyzing single-cell responses to ketamine administration, a multinational team of researchers has identified a potassium channel that contributes to the long duration of ketamine administration.
In two separate studies, researchers have identified how peripheral nerve injury can lead to increased pain sensitivity. The studies were published on May 25, 2022, in Nature and May 26, 2022, in Science, respectively. The mechanisms they identify could lead to new therapeutic approaches to chronic pain and/or pain hypersensitivity.
A target-agnostic search has yielded a patient-derived antibody that activated the innate immune system, researchers from Atreca and Stanford University reported in the May 4,2022, issue of the ProceedingsoftheNationalAcademyofSciences.
Age is the biggest risk factor for just about every common disease in high-income countries, which suggests that slowing down cellular aging would have massive effects on individual and public health. Delaying the average onset of Alzheimer’s disease by five years, for example, would roughly halve its prevalence. But in practice, there are no approved anti-aging medications.
